icone plus
Contact
Abonnez-vous aux actualités
Reason for request
Renewal of inclusion
Clinical Benefit
Substantial
The actual benefit of DOTAREM remains substantial.
Clinical Added Value
minor
DOTAREM offers a minor improvement in actual benefit (level IV) in terms of safety over gadolinium-based contrast media presenting a high (OMNISCAN, MAGNEVIST) or moderate (MULTIHANCE) risk of nephrogenic systemic fibrosis according to the European Medicines Agency classification.
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
QNeeCRCSjt658Lzr